Long-term impact of COVID-19 associated acute respiratory distress syndrome - 23/11/21
Highlights |
• | Most COVID-19 associated ARDS survivors have persistent symptoms beyond 8 months. |
• | At 8 months, COVID survivors with ARDS often have decreased exercise capacity. |
• | Almost all COVID survivors with ARDS develop at least one mental disorder. |
• | Female sex, non-Caucasian race, and Charlson>2 were risk factors for a worse MCS score on the SF-36. |
• | Female sex and COPD were independent risk factors for a worse PCS score on the SF-36. |
Abstract |
Objectives |
To determine the health status, exercise capacity, and health related quality of life (HRQoL) of COVID-19 associated acute respiratory distress syndrome (ARDS) survivors, 8 months after diagnosis.
Methods |
All eligible patients were interviewed and underwent a physical examination, chest X-ray, and 6 min walk test (6MWT). Scales to evaluate post-traumatic stress disorder, depression, anxiety, and HRQoL were applied.
Results |
Of 1295 patients, 365 suffered ARDS and 166 survived to hospital discharge. Five died after discharge and 48 were lost to follow-up. Of the 113 remaining patients, 81% had persistent symptoms. More than 50% of patients completed less than 80% of the theoretical distance on the 6MWT, 50% had an abnormal X-ray and 93% of patients developed psychiatric disorders. Mean SF-36 scores were worse than in the general population. After multivariate regression analysis, female sex, non-Caucasian race, and Charlson index>2 were independent risk factors for a worse mental health component summary score on the SF-36, and age was associated with a better prognosis. Female sex and chronic obstructive pulmonary disease were independently associated with a worse physical component summary score.
Conclusion |
COVID-19 associated ARDS survivors have long-term consequences in health status, exercise capacity, and HRQoL. Strategies addressed to prevent these sequelae are needed.
Le texte complet de cet article est disponible en PDF.Keywords : Long-term outcomes, Sequelae, COVID-19, SARS-CoV2, ARDS
Plan
Vol 83 - N° 5
P. 581-588 - novembre 2021 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.